Head and Neck Cancer (Oncology) Pipeline Forecast Report, H1, 2017 – Pharmaceutical Pipeline Guide [MRH]

Albany, New York, May 31, 2017:  Market Research Hub’s Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1070435

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

The Heada Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 87, 98, 5, 92, 17 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, and Preclinical and Discovery stages comprises 11, 6, 1, 15 and 3 molecules, respectively.

Head and Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope:

– The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Head and Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)
Browse Full Report with TOC @ http://www.marketresearchhub.com/report/head-and-neck-cancer-pipeline-review-h1-2017-report.html
Reasons to Buy:

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 

Table of Contents:
Table of Contents 2
Introduction 9
Head And Neck Cancer – Overview 10
Head And Neck Cancer – Therapeutics Development 11
Head And Neck Cancer – Therapeutics Assessment 51
Head And Neck Cancer – Companies Involved in Therapeutics Development 75
Head And Neck Cancer – Drug Profiles 167
Head And Neck Cancer – Dormant Projects 1190
Head And Neck Cancer – Discontinued Products 1200
Head And Neck Cancer – Product Development Milestones 1202
Appendix 1211

List of Tables
Number of Products under Development for Head And Neck Cancer, H1 2017 46
Number of Products under Development by Companies, H1 2017 48
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 49
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 50
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 51
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 52
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 53
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 54
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 55
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 56
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 57
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 58
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 59
Number of Products under Development by Universities/Institutes, H1 2017 60
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 62
Products under Development by Companies, H1 2017 63
Products under Development by Companies, H1 2017 (Contd..1), H1 2017 64
Products under Development by Companies, H1 2017 (Contd..2), H1 2017 65
Products under Development by Companies, H1 2017 (Contd..3), H1 2017 66
Products under Development by Companies, H1 2017 (Contd..4), H1 2017 67
Products under Development by Companies, H1 2017 (Contd..5), H1 2017 68
Products under Development by Companies, H1 2017 (Contd..6), H1 2017 69
Products under Development by Companies, H1 2017 (Contd..7), H1 2017 70
Products under Development by Companies, H1 2017 (Contd..8), H1 2017 71
Products under Development by Companies, H1 2017 (Contd..9), H1 2017 72
Products under Development by Companies, H1 2017 (Contd..10), H1 2017 73
Products under Development by Companies, H1 2017 (Contd..11), H1 2017 74
Products under Development by Companies, H1 2017 (Contd..12), H1 2017 75
Products under Development by Companies, H1 2017 (Contd..13), H1 2017 76
Products under Development by Companies, H1 2017 (Contd..14), H1 2017 77

 

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

 

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 866-997-4948 (US-Canada)

Tel: +1-518-621-2074

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/